Study of Proteins in Head and Neck Cancer Cells

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00896948
First received: May 9, 2009
Last updated: August 11, 2009
Last verified: October 2008
  Purpose

RATIONALE: Studying proteins in head and neck cancer cells in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at proteins in head and neck cancer cells.


Condition Intervention
Head and Neck Cancer
Genetic: Southern blotting
Genetic: TdT-mediated dUTP nick end labeling assay
Genetic: gene expression analysis
Genetic: protein expression analysis
Other: flow cytometry
Other: fluorescent antibody technique
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: immunologic technique

Study Type: Observational
Official Title: Novel Protein Regulator of Tumor Suppressor ARF & NF-κB

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Function and mechanism of LZAP in regulating ARF [ Designated as safety issue: No ]
  • Mechanism and biological consequences of LZAP inhibition of NF-κB [ Designated as safety issue: No ]
  • Determination of LZAP tumor suppressor activity [ Designated as safety issue: No ]

Study Start Date: May 2005
Detailed Description:

OBJECTIVES:

  • Define the function and mechanism of LZAP in regulating ARF.
  • Determine the mechanism and biological consequences of LZAP inhibition of NF-κB.
  • Determine if LZAP has tumor suppressor activity by conditional targeting of LZAP in mice.

OUTLINE: Using molecular laboratory techniques, this study examines the biochemical mechanisms by which LZAP activates transcriptional, tumor suppressive activity (both p53-dependent and p53-independent) of ARF and inhibits transcriptional, tumorigenic activity of NF-kB. LZAP regulation of newly identified ARF activities, such as S-phase delay and ARF-mediated B23 degradation are also evaluated. LZAP's tumor suppressive activity is assessed in vivo using a conditional knockout vector to target LZAP in mice and to observe for spontaneous and induced tumor formation. Laboratory analyses used to determine study endpoints include standard recombinant DNA, recombinant protein expression and purification, cell culture and transfection, cell labeling, reporter assays, flow cytometry, yeast-two hybrid, immunoprecipitation, immunoblotting, immunofluorescence, TUNEL assay, ELISA assay, Southern blotting, and protein and gene expression.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Head and neck cancer tumor cell line

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00896948

Locations
United States, Tennessee
Vanderbilt-Ingram Cancer Center - Cool Springs Recruiting
Nashville, Tennessee, United States, 37064
Contact: Wendell G Yarbrough    615-343-8840      
Vanderbilt-Ingram Cancer Center at Franklin Recruiting
Nashville, Tennessee, United States, 37064
Contact: Wendell G Yarbrough    615-343-8840      
Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232-6838
Contact: Clinical Trials Office - Vanderbilt-Ingram Cancer Center    800-811-8480      
Sponsors and Collaborators
Vanderbilt-Ingram Cancer Center
Investigators
Study Chair: Wendell G. Yarbrough, MD, FACS Vanderbilt-Ingram Cancer Center
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00896948     History of Changes
Other Study ID Numbers: CDR0000558974, VU-VICC-HN-0529, VU-VICC-IRB-050259
Study First Received: May 9, 2009
Last Updated: August 11, 2009
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
head and neck cancer

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms
Antibodies
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 16, 2014